Endometriosis and cannabis: why researchers study cannabinoid pathways

Understanding endometriosis

Endometriosis involves tissue resembling the endometrium outside the uterine cavity. It can be associated with severe menstrual pain, persistent pelvic pain, pain with sex, bowel symptoms, fatigue and sometimes infertility. Symptom severity does not always match the apparent size of lesions.

Why pain has several sources

Inflammation, nerve growth near lesions, adhesions, fibrosis and changes in central pain processing can all contribute. For some patients the nervous system becomes sensitized over time. This complexity helps explain why a single approach may not relieve every symptom.

Where the endocannabinoid system enters the picture

Endocannabinoid signaling participates in pain pathways, immune responses and reproductive tissue biology. Researchers have examined CB1, CB2 and related targets in endometriotic lesions and nerves. Such findings give a reason to investigate cannabinoids, but receptor expression alone is not evidence of clinical benefit.

What preclinical research can and cannot show

Experimental studies have explored whether changing cannabinoid signaling affects inflammatory activity, pain responses, lesion biology or fibrosis. Results depend on model, compound and dose. Animal or laboratory findings cannot establish that cannabis shrinks endometriosis lesions in people.

What patients report

Surveys and observational studies describe some women using cannabis for pain, sleep and related symptoms, with reports of relief. However, people who benefit may be more likely to continue using it; product composition and concurrent treatments also vary. Such studies cannot reliably determine cause and effect.

A feasibility randomized trial published in 2025 enrolled 12 participants, but only four completed the study. Recruitment and retention difficulties meant it could not establish treatment effectiveness. This trial illustrates why larger, well-conducted studies are still needed. 2025 feasibility trial ↗

Safety and individual decisions

THC may impair attention and coordination or increase anxiety in some people. Cannabinoid products can interact with medicines, and reproductive plans require additional caution. Evidence-supported gynecological care remains important; symptom improvement must not replace investigation or monitoring of the underlying disease.

Key conclusion

Endometriosis sits at the intersection of pain, immunity, hormonal biology and the ECS. This makes it an important research topic, not an established indication for cannabis as a disease-modifying therapy.

Source article and references

This article is an editorial adaptation of the Hebrew original.

Read the Hebrew source article ↗